Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) skidded in price Monday on reporting new ZYN002 data from STAR 1 and STAR 2 studies in patients with focal seizures at the AES2017.
The company is reporting new clinical data presented at the 2017 Annual Meeting of the American Epilepsy Society (AES) in Washington, D.C.
The key findings include that clinically meaningful responses to ZYN002, as measured by reductions in focal seizures from the baseline period of STAR 1, are correlated with continued treatment with ZYN002.
Patients who received ZYN002 (195mg during STAR 1 for three months and 390 milligrams for six months in STAR 2) for a total of nine months achieved a median reduction in seizures of 65%.
Patients who received ZYN002 (390mg for three months in STAR 1 and six months in STAR 2) achieved a 48% median reduction in seizures from baseline. In addition, ZYN002 was shown to be very well tolerated through nine months of exposure.
To quote Zynerba President Terri Browning Sebreet, "These new ZYN002 data are the first of their kind, showing that focal seizures in adults may be effectively treated by a transdermal gel delivery of pharmaceutically-produced cannabidiol.
"In this population of patients, continued treatment with ZYN002 was shown to significantly reduce seizure rates compared to baseline. Importantly, baseline seizure frequency appears to be an important indicator of response."
The news had the opposite effect on stock prices, which fell back $1.40, or 9.6%, to $13.18, within a 52-week trading range of $5.42 to $25.95.
